We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Autonomous Robot Performs COVID-19 Nasal Swab Tests

By HospiMedica International staff writers
Posted on 11 Aug 2020
Print article
The NSR autonomously takes nasal samples (Photo courtesy of Brain Navi Biotechnology)
The NSR autonomously takes nasal samples (Photo courtesy of Brain Navi Biotechnology)
A new robotic system performs nasal swab tests on its own, helping to prevent cross infections among people being examined.

The Brain Navi Biotechnology (Hsinchu, Taiwan) Nasal Swab Robot (NSR) is designed to automatically, independently, recognize a patient's facial structure and identify the nostril's location, and subsequently take a sample of nasal secretions. The target population are suspected cases of whooping cough, diphtheria, influenza, and other types of diseases caused by the coronavirus family of viruses, including SARS, MERS, and COVID-19. The NSR is equipped with a compact robotic arm and display screen mounted on a wheeled trolley.

The procedure is based on three-dimensional imaging to identify facial and nasal characteristics, without the use of external frames, in order to move through nostrils, twirl the swab to collect a nasopharyngeal swab sample, remove it, and place it in a vial. With the aid of NSR, suspect patients can be tested safely around the clock, sparing medical health care workers the need to done personal protective equipment (PPE) and enter the high-risk environment during sample collecting. NSR could also allow autonomous specimen collection in airports, borders, drive-ins, or medical institutions.

“The SARS outbreak 17 years ago was a profound experience, but also left me deep wounds after losing a dear friend while we were saving lives. So, I decided to develop a robot to help save lives and be the first human to test NSR,” said Jerry Chen, MD, CEO of Brain Navi Biotechnology. “We feel the suffering of thousands of colleagues and patients worldwide with the pandemic. So, we developed the NSR in just eight weeks. We took some essential functions of our Autopilot Brain Surgical Navigation Robot.”

Testing for COVID-19 involves inserting a 15 centimeter long swab into the nasopharyngeal space, a cavity between the nose and mouth for 15 seconds, and rotating it several times. The swabbing is then repeated on the other side of the nose to make sure enough material is collected. The swab is then inserted into a container and sent to a lab for testing.

Related Links:

Brain Navi Biotechnology
Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Disaster Preparedness Bed
Disaster Preparedness Bed
New
Mobile Cordless Cast Saw
CleanCast CSB-100

Print article

Channels

Critical Care

view channel
Image: The active substance TVEC led to a reduction in the size of the basal cell carcinoma in all study participants (Photo courtesy of 123RF)

Basal Cell Carcinoma Treatment Reduces Tumor Size, Improves Surgical Removal

Basal cell carcinomas, the most prevalent type of skin cancer, often appear in areas exposed to the sun, such as the face. Locally advanced tumors, in particular, present challenges for surgical treatment.... Read more

Surgical Techniques

view channel
Image: LumiSystem is the combination of two FDA approved products: LUMISIGHT (pegulicianine) and Lumicell Direct Visualization System (Photo courtesy of Lumicell)

Pioneering Technology Enables Real-Time Detection of Residual Breast Cancer During Lumpectomy

Breast cancer is the most frequently diagnosed cancer in women, with lumpectomies being the most common treatment approach. About 65% of women diagnosed with breast cancer undergo a lumpectomy, also referred... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.